Dow Up0.51% Nasdaq Up0.24%

Ariad Pharmaceuticals Inc. (ARIA)

6.52 Down 0.05(0.76%) Nov 21, 4:00PM EST
|After Hours : 6.56 Up 0.04 (0.61%) Nov 21, 6:13PM EST
ProfileGet Profile for:
Ariad Pharmaceuticals Inc.
26 Landsdowne Street
Cambridge, MA 02139
United States - Map
Phone: 617-494-0400
Fax: 617-494-8144

Index Membership:N/A
Full Time Employees:307

Business Summary 

ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Ariad Pharmaceuticals Inc.

Corporate Governance 
Ariad Pharmaceuticals Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 9. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Harvey J. Berger M.D., 64
Principal Founder, Chairman, Chief Exec. Officer, Pres and Chairman of Exec. Committee
Mr. Edward M. Fitzgerald , 59
Chief Financial Officer, Exec. VP and Treasurer
Dr. Timothy P. Clackson Ph.D., 49
Pres of R&D and Chief Scientific Officer
Dr. Daniel M. Bollag Ph.D., 53
Sr. VP of Regulatory Affairs and Quality
Mr. Martin J. Duvall , 52
Chief Commercial Officer and Exec. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders